DAAhoidot

DAAhoidot, or direct-acting antiviral therapy for hepatitis C, refers to a group of regimens that directly inhibit hepatitis C virus replication. These medicines target viral proteins such as NS5A, NS5B polymerase, and NS3/4A protease, thereby blocking the virus’s ability to multiply.

DAA regimens are the standard of care for chronic hepatitis C infection. They come in several combinations, including pan-genotypic options that work across most or all HCV genotypes. Common regimens include combinations of sofosbuvir with ledipasvir or velpatasvir, and combinations of glecaprevir with pibrentasvir. Treatment durations typically range from 8 to 12 weeks, with shorter courses possible for some non-cirrhotic patients and longer or more specialized regimens used for those with cirrhosis or previous treatment failure. Ribavirin is now used infrequently, mainly in specific difficult cases.

Efficacy of DAAhoidot is high, with sustained virologic response (SVR) rates usually in the mid to high 90s across genotypes. Cure is effectively permanent for most people, and SVR is associated with reduced risk of liver-related complications. However, prior or advanced liver disease, certain drug interactions, and specific patient factors can influence regimen choice and duration. Resistance-associated substitutions exist but rarely limit success with modern pan-genotypic regimens.

Safety and monitoring are important elements of care. DAAs are generally well tolerated, with mild side effects such as fatigue or headache. Before starting therapy, clinicians assess genotype, fibrosis stage, kidney and liver function, and potential drug interactions. Access and cost remain considerations in some regions, though prices and availability have improved substantially in recent years.